CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Ananda Pharma GmbH is developing a plant-derived active pharmaceutical ingredient for treating specific heart diseases. This innovative compound stabilizes heart cell function and improves energy metabolism, offering a new approach to diagnosing and managing ischemic heart conditions.
Ananda Pharma GmbH qualified a plant derived active pharmaceutical ingredient (API) for specific heart diseases.
In nanomolar doses the substance protects cardiomyocytes by stabilizing the Na+/K+ -ATPase.
The API enables ischemic preconditioning and has a balancing effect on the energy metabolism of cardiomyocytes by enhancing the turnover of lactate to ATP.
The specific mode of action conveys a larger therapeutic range which means a smaller risk for unwanted side effects compared to similar sub…
ANANDA PHARMA GMBH
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
